Calliditas Therapeutics AB ADR (CALT): Price and Financial Metrics Recent IPO

Calliditas Therapeutics AB ADR (CALT) Recent IPO

Today's Latest Price: $32.30 USD

0.07 (0.22%)

Updated Nov 24 4:00pm

Add CALT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CALT Stock Price Chart Interactive Chart >

Price chart for CALT

CALT Price/Volume Stats

Current price $32.30 52-week high $38.00
Prev. close $32.23 52-week low $19.00
Day low $31.81 Volume 6,700
Day high $32.41 Avg. volume 50,352
50-day MA $27.23 Dividend yield N/A
200-day MA $0.00 Market Cap 774.20M

Calliditas Therapeutics AB ADR (CALT) Company Bio

Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

CALT Latest News Stream

Event/Time News Detail
Loading, please wait...

CALT Latest Social Stream

Loading social stream, please wait...

View Full CALT Social Stream

Latest CALT News From Around the Web

Below are the latest news stories about Calliditas Therapeutics AB that investors may wish to consider to help them evaluate CALT as an investment opportunity.

Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma

Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation Mallinckrodt (MNK) stock moved up as the market responded to merger rumors for the company. While the name of the likely acquirer is kept under covers, the rumors have helped the company stock, which has seen sharp decline in the recent...

Avisol Capital Partners on Seeking Alpha | August 16, 2020

Calliditas to buy controlling stake in Genkyotex

Calliditas Therapeutics ([[CALT]] -0.3%) has agreed to acquire a 62.7% interest in Genkyotex through an off-market block trade of 7.2M Genkyotex, for €20.3M at €2.80/share.The deal adds late-stage orphan pipeline asset and platform in inflammation and fibrosis, to Calliditas's pipeline.Genkyotex's lead clinical candidate, setanaxib (GKT831), is in Phase 2 study for Primary Biliary Cholangitis...

Seeking Alpha | August 13, 2020

Read More 'CALT' Stories Here

CALT Price Returns

1-mo 27.82%
3-mo 37.51%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7581 seconds.